April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Pharmacologic Treatments of a Mouse Model of Age-Related Macular Degeneration Caused by All-Trans-Retinal Clearance Delay
Author Affiliations & Notes
  • T. Maeda
    Ophthalmology,
    Case Western Reserve University, Cleveland, Ohio
  • A. Maeda
    Ophthalmology,
    Case Western Reserve University, Cleveland, Ohio
  • M. Motosky
    Pharmacology,
    Case Western Reserve University, Cleveland, Ohio
  • S. Satsumi Roos
    Pharmacology,
    Case Western Reserve University, Cleveland, Ohio
  • J. Tang
    Ophthalmology,
    Case Western Reserve University, Cleveland, Ohio
  • K. Palczewski
    Pharmacology,
    Case Western Reserve University, Cleveland, Ohio
  • Footnotes
    Commercial Relationships  T. Maeda, None; A. Maeda, None; M. Motosky, None; S. Satsumi Roos, None; J. Tang, None; K. Palczewski, None.
  • Footnotes
    Support  NIH grants EY019031(AM), EY09339 (KP), P30 EY11373(KP), and EY08123(KP)
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 780. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Maeda, A. Maeda, M. Motosky, S. Satsumi Roos, J. Tang, K. Palczewski; Pharmacologic Treatments of a Mouse Model of Age-Related Macular Degeneration Caused by All-Trans-Retinal Clearance Delay. Invest. Ophthalmol. Vis. Sci. 2009;50(13):780.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy and safety of current potential medications for age-related macular degeneration (AMD) in a mouse model.

Methods: : Pharmacologic treatments including anti-oxidative agents (ascorbic acid, -lipoic acid, -tocopherol, MnTBAP and butylated hydroxytoluene), immunosuppressant (rapamycin; also has anti-VEGF effects), retinoid cycle inhibitor (retinylamine), artificial chromophore, 9-cis-retinyl acetate (9-cis-R-Ac) were conducted for a mouse model of AMD caused by all-trans-retinal clearance delay with lacks of ATP-binding cassette transporter 4 (ABCA4) and retinol dehydrogenase 8 (RDH8).

Results: : All of the medications partially improved atrophic changes of Rdh8-/-Abca4-/- retina, and retinylamine expressed the best treatment effects among them. Significant reduction of complement deposition at Bruch’s membrane was observed in rapamycin-treated mice, even through severity of retinal degeneration was similar to anti-oxidants and 9-cis-R-Ac treated mice. Rapamycin treatment to 6 months old Rdh8-/-Abca4-/- mice for 4 months prevented the growth of CNV without any change of VEGF level.

Conclusions: : Mechanism based therapy with retinylamine demonstrated the best treatment effects on Rdh8-/-Abca4-/- mice, and understanding of fundamental problems in AMD is required to develop effective therapies.

Keywords: age-related macular degeneration • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×